A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx Paclitaxel-Coated Conformer Coronary Stent

Trial Profile

A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx Paclitaxel-Coated Conformer Coronary Stent

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Coronary disorders; Myocardial ischaemia; Restenosis; Unstable angina pectoris
  • Focus Registrational; Therapeutic Use
  • Acronyms TAXUS-II
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 13 Oct 2009 Final 5-year results published in Circulation.
    • 29 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top